预约演示
更新于：2025-05-16
Botulinum toxin(UroGen Pharma Ltd.)
更新于：2025-05-16
概要
基本信息
非在研机构- |
权益机构- |
最高研发阶段临床2期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
关联
5
项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的临床试验ChiCTR2400080899
Study on the Safety and Efficacy of Extracorporeal Shock Wave Combined with Botulinum Toxin in the Treatment of Children with Spastic Cerebral Palsy
开始日期2024-02-19 |
申办/合作机构- |
IRCT20130523013442N33
Comparison of ultrasound guided injection of botulinum toxin at the origin of plantar fasciitis with injection of botulinum toxin by Babcock method in the treatment of plantar fasciitis
开始日期2023-09-23 |
JPRN-jRCT1090220265
The study for the effect of botulinum toxin for upper limb spasticity - The effect of botulinum toxin for upper limb spasticity
开始日期2016-11-24 |
申办/合作机构 |
100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的临床结果
登录后查看更多信息
100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的转化医学
登录后查看更多信息
100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的专利（医药）
登录后查看更多信息
4,164
项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的文献（医药）2025-12-01·Techniques in Coloproctology
Efficacy and safety of botulinum toxin injection in the management of chronic symptomatic anal fissure: a systematic review and meta-analysis of randomized controlled trials
Review
作者: Abdelaziz, H ; Gruber, M ; Thippeswamy, K Maradi ; Abdel-Dayem, M
BACKGROUND:
Anal fissure is one of the most painful anal conditions. Various management options are available, including topical nitrites, calcium channel blockers, botulinum toxin injection, and lateral internal sphincterotomy. This study aimed to assess the efficacy and safety of botulinum toxin A (BT) injection for the management of symptomatic chronic anal fissures by conducting a systematic review of the literature and meta-analysis of published randomized controlled trials (RCTs).
METHODS:
A systematic search was conducted using the Embase and Medline search platforms. The search identified 264 papers published from January 1974 to December 2023, 35 of which were RCTs. Meta-analysis was performed on the collected data with a random effects model using Freeman-Tukey arcsine-transformed proportions. A p value less than 0.05 was considered to indicate statistical significance. The I2 test was used to assess heterogeneity.
RESULTS:
A total of 1532 patients were included. After data were pooled, 1117 patients out of 1532 (72.7%) demonstrated healing of the fissure after the first injection of BT (P < 0.001, I2 = 86.6%). Subgroup analysis was performed on the basis of the follow-up period in months. Nine studies reported that a second BT injection was needed for patients who did not respond after the initial injection. Twenty-nine out of 38 patients (78.5%) responded to the second injection (p < 0.001, I2 = 50.6%). Complications were observed in 88 out of 1532 patients (4.02%) (p < 0.001, I2 = 60.2%).
CONCLUSION:
BT injection is a safe treatment approach for chronic symptomatic anal fissures, typically associated with only minor, temporary complications. Evidence also supports the use of repeat injections for managing recurrent or persistent symptoms.
2025-12-01·Techniques in Coloproctology
Urge fecal incontinence: are intramural rectal injections of botulinum toxin a long-term treatment option?
Article
作者: Baumstarck, Karine ; Vitton, Véronique ; Onana Ndong, Philippe
BACKGROUND AND AIMS:
Unsuccessful first-line conservative treatments for managing fecal incontinence (FI) lead to considering predominantly invasive options, posing challenges in terms of cost and patient acceptance of benefit/risk ratio. Recent data from a prospective randomized study have highlighted intramural rectal botulinum toxin (BoNT/A) injection as a promising minimally invasive alternative for urge FI, demonstrating efficacy at 3 months but lacking long-term evidence. This study aimed to evaluate the sustained efficacy and injection frequency of intramural rectal BoNT/A injection in the treatment of urge FI.
METHODS:
This retrospective monocentric study enrolled all patients who underwent intramural rectal BoNT/A injection for urge FI after failed conservative therapy or sacral neuromodulation (SNM). Injections were administered during sigmoidoscopy, delivering 200 U of BoNT/A at 10 circumferentially distributed sites. Treatment effectiveness was assessed using the Cleveland clinic incontinence score (CCS) and a visual analog scale (VAS) to measure the severity of discomfort related to episodes of fecal urgency, with reinjection performed upon symptom recurrence.
RESULTS:
In total, 41 patients (34 females) were included, with a median follow-up of 24.9 (range 3.2-70.3) months. Overall, 11 patients had previously failed sacral nerve stimulation. Significant reductions were observed in the CCS (median 11 versus 7, p = 0.001) and VAS symptoms (median 4, range 0-5 versus median 2, range 0-5, p = 0.001). In total, 22 patients (53%) experienced a reduction in the CCS by over 50%. The median interval between intramural rectal BoNT/A injections was 9.8 months (range 5.3-47.9 months).
CONCLUSIONS:
This study provides the first evidence of the sustained efficacy of intramural rectal BoNT/A injection for urge FI. Further investigations are warranted to refine patient selection and reinjection criteria, evaluate socioeconomic impacts, and compare rectal BoNT/A injection with other therapeutic modalities.
2025-07-01·NEUROCHIRURGIE
Comprehensive pain management in spinal surgery: The role of botulinum toxin
Letter
作者: Sophie, Galmiche ; Pierre-Jacques, Finiels ; Marie, De Boutray ; Dominique, Batifol
The use of botulinum toxin in pre- and post-operative management of pain in spinal surgery is described, following a specific administration protocol. The initial encouraging results (particularly the absence of opioid use in the post-operative period) support the potential role of BoNT-A (Botulinum Neurotoxin type A) as a targeted therapeutic option in this specific clinical setting.
6
项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的新闻（医药）2024-11-21
NEWS RELEASE: Merz Therapeutics and S3 Connected Health Pioneer New Digital Health Solution, iFlexo, for People Living with Post-Stroke Spasticity
Dublin/Frankfurt — Merz Therapeutics launches iFlexo, a personalized digital solution aimed at enhancing rehabilitation for people with post-stroke spasticity as part of its ongoing commitment to supporting stroke survivors.
The app, developed in collaboration with S3 Connected Health, provides targeted exercises and rehabilitation programs specifically aimed at improving mobility for those with mild to moderate spasticity. By offering guided routines, iFlexo aims to help stroke survivors regain independence and improve their overall quality of life. Merz Therapeutics is the first and only neurotoxins pharmaceutical company to offer a platform to support self-rehabilitation.
iFlexo, developed and operated on S3 Connected Health’s digital health platform Affinial, was released in August 2024 and is available for iOS and Android in France. Developing iFlexo on Affinial enabled the creation of a differentiated user experience optimized for post-stroke patients. An accelerated time to market of just five months was achieved thanks to Affinial’s range of pre-built, customizable digital health services. The Affinial platform enables iFlexo to scale and evolve by addressing current and future compliance, legal, cybersecurity, and regulatory requirements. During the pilot stage in France, it gained significant interest from patients, clinicians, and key opinion leaders.
Dr. Alexandre Bertholon, Physical Medicine & Rehabilitation at Le Clos Champirol, says: “iFlexo is a promising solution in physical rehabilitation, offering a much-needed response to the current challenges in the field. It enables patients to engage in self-rehabilitation at home, focusing on their personal goals. This platform not only supports patients but also enhances efficiency for healthcare professionals by optimizing and extending the results of rehabilitation. It demonstrates how new solutions can improve patient outcomes and make care more effective.”
Up to one-third of stroke survivors experience spasticity, a condition that can severely limit their ability to perform everyday tasks, often leaving them reliant on others.[1] For these individuals, personalized botulinum neurotoxin injection therapy as part of a multimodal approach can improve muscle tone and consequently patient’s mobility and quality of life. [2]
Merz Therapeutics and S3 Connected Health are committed to providing better outcomes for more patients and are currently working on expanding the solution to more countries, starting in the coming months.
[1] Ali, A., McCarthy, A.D., Reeves, M. et al. Sheffield Adaptive Patterned Electrical Stimulation (SHAPES) Therapy for Post Stroke Arm spasticity: study protocol for a 3-arm, a partially blinded, randomised controlled trial. BMC Neurol 24, 437 (2024).
[2] Otero-Luis I, Martinez-Rodrigo A, Cavero-Redondo I, Moreno-Herráiz N, Martínez-García I, Saz-Lara A. Effect of Botulinum Toxin Injections in the Treatment of Spasticity of Different Etiologies: An Umbrella Review. Pharmaceuticals. 2024; 17(3):310.
Merz Therapeutics
Merz Therapeutics GmbH is dedicated to improving the lives of patients around the world. With its relentless research, development, and culture of innovation, Merz Therapeutics strives to serve unmet patient needs and realize better outcomes. Merz Therapeutics seeks to address the unique needs of people who suffer from movement disorders, neurological conditions, liver disease, and other health conditions that severely impact patients’ quality of life.
Merz Therapeutics is headquartered in Frankfurt am Main, Germany and is represented in more than 90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz Therapeutics GmbH is part of the Merz Group, a privately held, family-owned company that has dedicated 115 years to developing innovations that serve unmet patient and customer needs.
For more information, please visit:
S3 Connected Health
S3 Connected Health is the specialist digital health partner for life science companies, developing regulated digital health solutions that improve the lives of people with acute and chronic conditions. It has delivered award-winning, regulatory-compliant solutions across 20 therapy areas and in more than 50 countries. The company’s scalable and secure solutions improve disease management, differentiate pharmaceutical products and deliver new therapeutic approaches.
Affinial, S3 Connected Health’s digital health platform, offers partners the opportunity to develop customized digital health solutions tailored to specific patient, device or disease needs. The platform’s pre-built services provide best practice implementation to ensure successful solution adoption and an accelerated time-to-market.
For more information, please visit:
The opinions expressed in this news release are the author’s only and do not necessarily reflect those of Medical Design & Outsourcing or its employees.
2024-05-21
ROSEMONT, Ill., May 21, 2024 /PRNewswire/ -- The American Academy of Physical Medicine and Rehabilitation (AAPM&R) has today released spasticity guidance to establish a framework that reviews treatment options, endorses the highest quality of evidence-based care, and encourages research where there are knowledge gaps.
Spasticity is a group of symptoms characterized by muscle tightening or reduced stretchability following injuries to or conditions affecting the brain and spinal cord, including stroke, cerebral palsy, multiple sclerosis, traumatic brain injury, or spinal cord injuries.
Continue Reading
When spasticity symptoms are recognized early, physicians can better manage and treat it through a range of therapies.
Post this
Spasticity symptoms include uncontrollable rhythmic, shaking movements, cramping, spasms, and tight, rigid muscles that cannot be stretched easily and may cause pain. Other symptoms may include incoordination, fatigue, weakness, and impaired motor control.
Spasticity is often delayed and an evolving condition. If left untreated, spasticity can cause muscles to become stuck, leading to joint deformity.
"Physicians have a growing toolbox of treatments for spasticity," said guidance author Dr. Preeti Raghavan, MBBS. "When patients or their caregivers recognize the symptoms of spasticity and seek treatment for those symptoms, we have even better chances to manage and treat their spasticity symptoms through a range of therapies."
The first line of treatment and management interventions aimed at reducing the effects of spasticity is rehabilitative therapy. Simple, non-pharmacologic interventions that facilitate movement and improve function should be attempted before resorting to treatments that carry more risks and side effects.
Therapeutic interventions can be used individually or in combination, including oral medications, injectables such as Botulinum toxin, and surgical options. An integrated, multi-disciplinary, goal-centered management approach is essential to providing long-term, comprehensive care for spasticity.
PM&R physicians are leaders in recovery and regularly care for patients with conditions that cause spasticity, such as rehabilitating patients post-stroke or other conditions causing spasticity. Because of this, PM&R physicians have the necessary specialized equipment, supplies, and prior authorization procedures in place to treat spasticity patients and work with their insurance providers. The guidance is published in the PM&R Journal.
The American Academy of Physical Medicine and Rehabilitation is the national medical specialty organization representing more than 10,000 physicians specializing in physical medicine and rehabilitation. PM&R physicians, also known as physiatrists, treat a wide variety of medical conditions affecting the brain, spinal cord, nerves, bones, joints, ligaments, muscles and tendons. PM&R physicians evaluate and treat injuries, illnesses and disability and are experts in designing comprehensive, patient-centered treatment plans. Physiatrists utilize cutting-edge as well as time-tested treatments to maximize function and quality of life.
SOURCE American Academy of Physical Medicine and Rehabilitation
2024-01-09
Advice from a board-certified dermatologist on seeking cosmetic treatments
ROSEMONT, Ill., Jan. 9, 2024 /PRNewswire/ -- With a rise in both public accessibility and visibility, cosmetic treatments are more popular than ever. Whether your New Year's resolution is to improve your health or to look and feel your best, the most important thing to remember is that your results depend largely on the skills and knowledge of the person performing your treatment.
"There is no one-size-fits-all or 'cookie cutter' approach to combat the signs of aging because aging looks different on everyone. On the flipside, there is no one cosmetic treatment to address all of these changes," said Lauren Fine, MD, FAAD, a board-certified dermatologist in Chicago. "The best cosmetic outcomes are often achieved with a comprehensive approach, starting with skincare at home, combined with other in-office treatments recommended by a board-certified dermatologist that is taking all of these factors into account when recommending a cosmetic treatment that is best for you."
While over-the-counter options are available, they may not be able to provide the results that a cosmetic procedure can deliver. Common treatment options include botulinum toxin, fillers, and lasers. Botulinum toxin is used to diminish signs of aging, including frown lines between the eyebrows and crow's feet, as well as for hyperhidrosis (excessive sweating). Most people see results within 3 to 7 days and results can last about 3 to 4 months—even longer when treating excessive sweating. Fillers are also used to diminish signs of aging by restoring lost fullness to the face, lips, and hands, as well as to lessen scars and erase fine lines. Most fillers provide immediate results; however, they tend to be temporary and require repeat treatments. Lasers can treat a variety of concerns including stretch marks, scars, the removal of unwanted hair, and age spots. It is important to note that lasers cannot fully remove stretch marks or scars, but rather make them less noticeable. Multiple sessions are often necessary to see results when undergoing this form of treatment.
Before undergoing any cosmetic procedure, Dr. Fine and the AAD recommend asking the following questions:
What are the doctor's credentials and are they board-certified? Remember, dermatologists are physicians with extensive education, training, and experience in keeping the skin, hair, and nails healthy.
How many of these particular cosmetic surgery procedures has the physician performed? The procedure should be one that the doctor performs regularly. Ask to see before-and-after photos of previous patients.
What result can I expect and are there any risks? Because your results depend largely on the skill and experience of the person performing the procedure, it is important to select a board-certified physician. A dermatologist can tell you if the procedure will deliver the desired results, based on the condition of your skin as well as your age and health.
If you have specific cosmetic concerns or questions about a particular treatment, the best place to start is with a board-certified dermatologist.
"While some cosmetic procedures may look easy to perform, understanding how to safely treat patients and deliver the best desired result requires an in-depth medical knowledge of the skin," shared Dr. Fine. "In the age of social media and information overload, anyone can tout themselves as an expert. Going to a board-certified dermatologist for cosmetic treatments ensures that you will receive effective results from an expert with a deep understanding of the skin."
If you're considering a cosmetic procedure, visit aad.org/findaderm to find a board-certified dermatologist in your area.
More Information
Cosmetic treatments
Cosmetic treatment safety
AAD B-Roll Library
About the AAD
Headquartered in Rosemont, Ill., the American Academy of Dermatology, founded in 1938, is the largest, most influential and most representative of all dermatologic associations. With a membership of more than 20,800 physicians worldwide, the AAD is committed to advancing the diagnosis and medical, surgical, and cosmetic treatment of the skin, hair, and nails; advocating high standards in clinical practice, education and research in dermatology; and supporting and enhancing patient care because skin, hair, and nail conditions can have a serious impact on your health and well-being. For more information, contact the AAD at (888) 462-DERM (3376) or aad.org. Follow @AADskin on Facebook, TikTok, Pinterest and YouTube and @AADskin1 on Instagram.
SOURCE American Academy of Dermatology
100 项与 Botulinum toxin(UroGen Pharma Ltd.) 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | Botulinum toxin(UroGen Pharma Ltd.) | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 尿失禁 | 临床2期 | 以色列 | 2016-10-01 | |
| 膀胱过度活动症 | 临床2期 | 以色列 | 2016-10-01 | |
| 间质性膀胱炎 | 临床2期 | - | - | |
| 间质性膀胱炎 | 临床2期 | - | - |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
N/A | 29 | 願蓋廠鹹製憲網艱齋築(築膚夢繭糧壓築壓蓋夢) = 糧繭艱顧鏇蓋獵醖鬱襯 衊鬱積齋範願觸艱製鏇 (獵遞餘製觸繭襯夢製餘, 5.4) 更多 | 积极 | 2024-02-22 | |||
N/A | 68 | Bimedial recti toxin injections | 鏇製襯願廠願願壓憲廠(遞顧艱簾醖壓憲齋構鏇) = 鬱顧積餘憲壓鹹鑰鹹蓋 鏇顧簾範顧齋繭夢衊壓 (窪壓廠製範範餘膚顧鹽 ) | 积极 | 2024-02-22 | ||
(Strabismus surgery) | 積遞醖製壓願蓋製憲衊(窪壓衊選繭鏇窪鹹鏇糧) = 繭構窪鹹醖蓋窪遞廠鹽 餘築廠鏇餘鑰壓鹹衊夢 (選製餘艱鬱餘艱壓艱鹹 ) 更多 | ||||||
N/A | - | 夢願鏇鬱觸簾遞窪夢艱(鏇餘廠製醖願鏇獵膚顧) = 範繭膚醖蓋鬱鹹願衊淵 製鹽糧壓衊構衊窪壓鏇 (餘觸顧觸艱糧廠鑰獵觸 ) 更多 | - | 2024-02-22 | |||
N/A | - | 44 | 糧糧窪壓鏇構簾齋窪範(選鏇餘淵窪顧壓襯膚繭) = intense pain during ( 2 ) or after ( 3, transitory ) infiltration and transitory decrease in manual strength ( 3 ) 構糧糧築構遞蓋簾蓋網 (願膚築餘築齋積襯構壓 ) 更多 | 积极 | 2023-10-11 | ||
N/A | - | 製艱淵廠鹽製簾鬱網範(廠襯獵觸遞餘糧壓壓廠) = 鑰顧獵襯艱網積鬱選齋 選襯鬱窪齋繭憲構鏇衊 (糧淵膚積製遞鹽襯顧襯 ) 更多 | - | 2023-10-01 | |||
製艱淵廠鹽製簾鬱網範(廠襯獵觸遞餘糧壓壓廠) = 選壓鬱壓顧鹽構繭窪簾 選襯鬱窪齋繭憲構鏇衊 (糧淵膚積製遞鹽襯顧襯 ) 更多 | |||||||
N/A | - | 淵鹽鹽選鹹繭獵築觸憲(齋鬱鑰鏇簾艱衊醖繭選) = in four patients 構觸鏇壓獵憲網範築簾 (膚繭蓋範鏇鑰艱憲鹹範 ) 更多 | - | 2023-08-27 | |||
N/A | 578 | 壓壓遞簾繭淵網鬱鏇顧(淵簾鬱淵網鹽網範願製) = 築襯齋範憲簾醖憲膚廠 構築膚艱繭繭齋積鑰鏇 (鹹壓簾鹽積鹽遞膚鏇鹽 ) 更多 | 积极 | 2023-08-27 | |||
積築觸艱餘蓋艱憲選鏇(鬱艱夢觸窪願廠積願構) = 淵蓋繭選憲壓鑰繭醖憲 淵願簾網艱製鏇鹽壓積 (選製鑰窪鹽蓋膚廠襯壓 ) | |||||||
N/A | 152 | Preseptal Botulinum Toxin Injection | 遞範觸築糧獵遞醖觸獵(築艱齋遞選鏇築餘鏇憲) = 窪憲齋簾鹹鏇壓夢膚齋 構獵網築繭衊範範窪選 (願範鏇糧鹹觸醖範築蓋 ) | 积极 | 2023-04-25 | ||
Pretarsal Botulinum Toxin Injection | 遞範觸築糧獵遞醖觸獵(築艱齋遞選鏇築餘鏇憲) = 廠蓋齋壓顧選築壓範積 構獵網築繭衊範範窪選 (願範鏇糧鹹觸醖範築蓋 ) | ||||||
N/A | 5 | 鹹醖淵憲鏇鹹願憲艱選(醖膚醖積獵鏇膚憲齋襯) = seen only in 1 patient after the first injection 鹹衊遞淵壓築獵範廠簾 (憲衊窪築醖繭憲衊壓淵 ) | 积极 | 2023-04-25 | |||
N/A | 10 | 艱範築廠膚衊淵繭醖鏇(醖鹽積鹽廠遞築憲糧壓) = 願築醖襯觸窪選鬱壓糧 齋鑰製獵憲壓淵構糧顧 (鑰壓衊鏇願鑰衊遞餘積 ) | - | 2023-03-17 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用